$Hims & Hers Health Inc.(HIMS)$ Transitioning from selling CSPs to officially owning a lot of HIMS feels like the right move now that the stock is testing the $30 to $31 range. This zone is particularly interesting because it represents a major gap-fill opportunity from the April earnings beat, and after the massive haircut the stock has taken, this level looks like a high-probability bounce point. By electing to take assignment instead of rolling the contract again, the focus moves toward capitalizing on a potential recovery rather than just collecting small slices of premium. It has been a long process of avoiding assignment while the price searched for a bottom, but with the technical setup looking this ripe, it is time to shift gears and hold the underlying for the next leg of the cycle.